Peptide steady state is a precisely calculable quantity — not a guess. This guide walks through the full mathematical framework, three real compound worked examples, and why running these calculations manually in a spreadsheet introduces errors that silently distort your protocol.
When you inject a peptide on a regular schedule, something happens that a reconstitution calculator or a one-time decay curve cannot show you: the compound begins to accumulate. Each new dose lands on top of whatever the previous dose left behind. Over repeated injections at a fixed interval, serum concentrations rise toward a plateau — a steady state — where the amount entering the body per dose exactly equals the amount being eliminated per dosing interval.
That plateau concentration is not random. It is determined entirely by two variables: the compound's elimination half-life and your dosing interval. And it is fully calculable before you take your first dose.
Understanding how to calculate peptide steady state matters because the plateau is where your protocol actually lives. The first injection is a transient event. Week 4 on a GH secretagogue stack — when concentrations have stabilised — is where the pharmacokinetic reality of your protocol becomes fixed. If you do not know what that reality looks like, you are flying blind on dosing frequency, timing, and trough coverage.
Steady state (Css) is the condition in which the total body drug concentration no longer increases with each successive dose. It is reached when the rate of drug input — one dose every τ hours — equals the rate of drug elimination over that same interval.
For any compound following first-order elimination kinetics (which describes all peptides and GLP-1 agonists), steady state is approached asymptotically. You never technically reach it, but for practical purposes it is considered achieved at 4–5 elimination half-lives from the first dose. At that point, concentrations are within 3–6% of their true plateau value.
The key pharmacokinetic parameters that define steady state for your protocol are:
Every one of these parameters is a direct function of just two numbers: your compound's elimination half-life (t½) and your dosing interval (τ). The formulas are exact.
Here is the complete calculation framework for peptide steady state, in the order you apply it. Each step builds on the previous one.
The elimination rate constant converts a half-life value into the fraction of drug eliminated per unit time. It is the fundamental parameter that drives every downstream calculation.
Racc tells you exactly how much higher your steady-state peak concentration will be compared to the peak after your very first injection. A value of 1.0 means no accumulation. A value of 2.0 means plateau concentrations are double the first dose. This is the single most important number for understanding what your protocol is doing.
Once you have Racc, computing the plateau peak and trough is straightforward. You need an estimate of your first-dose peak concentration (Cmax,1), which depends on dose and volume of distribution — or you can treat it as a relative multiplier to understand the ratio.
PTR quantifies how dramatically concentrations swing within a dosing interval at steady state. A PTR of 1.0 means flat levels. A high PTR means large swings — which matters if you are trying to maintain consistent receptor occupancy between doses.
The practical rule is 4–5 half-lives from the first dose. This gives you the calendar date at which your protocol has stabilised and your peak/trough values match the Css calculations above.
The same five steps produce radically different pharmacokinetic profiles depending on the compound. The following three examples cover the full range of half-life behaviours seen in common peptide and GLP-1 protocols.
t½ ≈ 2 hours (published pharmacokinetic data). Dosing interval τ = 8 hours. Classic short-acting peptide protocol.
Interpretation: Ipamorelin dosed TID accumulates by only 6.7% above single-dose levels — because the 8-hour dosing interval is four half-lives, allowing near-complete clearance before each injection. But the 16× peak-to-trough ratio reveals extreme intra-cycle variability: concentrations are 16 times higher immediately after injection than they are immediately before the next one. If consistent receptor occupancy between doses is a goal, the TID frequency is not achieving it at the trough.
t½ ≈ 8 days = 192 hours (Drug Affinity Complex extends half-life substantially). Dosing interval τ = 168 hours (7 days). Frequently co-administered with ipamorelin.
Interpretation: CJC-1295 DAC behaves oppositely to ipamorelin. Because its 8-day half-life exceeds the 7-day dosing interval, 54.6% of the previous dose remains at trough. Concentrations accumulate significantly — plateau peak is 2.2× your first-dose peak — and steady state does not arrive until approximately week 5. Anyone adjusting their dose in the first month is changing the protocol before it has stabilised.
t½ ≈ 7 days = 168 hours (acylated GLP-1 analogue with extended PK profile). Dosing interval τ = 168 hours. Special case: t½ = τ exactly.
Interpretation: When t½ = τ, Racc is always exactly 2.0× — a mathematical identity. Exactly half of each dose is eliminated before the next one arrives. At steady state, semaglutide concentrations oscillate between 2× and 1× your first-dose peak in a predictable, symmetrical sawtooth. Anyone reporting plateau effects beginning around week 4–5 is describing steady-state pharmacokinetics, not a delayed mechanism of action.
The three examples above produce visually distinct concentration-time curves. Understanding the shape of your curve is as important as knowing the steady-state endpoint values.
Compounds like ipamorelin, GHRP-2, CJC-1295 no-DAC, and BPC-157 produce sharp concentration spikes that decay steeply between doses. The curve looks like a series of tall, narrow peaks separated by near-zero valleys. Accumulation is minimal — Racc is close to 1.0 — but the peak-to-trough ratio is enormous. What this means practically: the compound is only pharmacologically active for a few hours around each injection. Dosing frequency, not steady-state accumulation, is the dominant design variable.
Compounds in this range — testosterone enanthate (t½ ≈ 4.5 days), tirzepatide (t½ ≈ 5 days), peptide sequences in the 6–24-hour range — produce a classic saw-tooth accumulation pattern. Each dose adds onto a meaningful residual from the previous one. The curve rises over the first 3–4 doses and then oscillates in a stable band. Accumulation is significant but bounded. Racc typically falls between 1.3–2.5×. Steady state arrives within 1–2 weeks.
CJC-1295 DAC, semaglutide, testosterone undecanoate, and insulin degludec fall into this category. Each dose clears only partially before the next, producing a gradual multi-week rise toward plateau. The curve looks like a climbing staircase that eventually flattens. The key mistake with these compounds is adjusting dose before plateau is reached — which means adjusting before you have seen the pharmacokinetic reality you will be living at. Racc of 2.0× or higher means week-1 concentrations are half (or less) of what they will be at steady state.
The five calculation steps above look manageable on paper. In practice, running them continuously across a multi-compound protocol in a spreadsheet introduces failure modes that are difficult to detect and easy to ignore.
The formula for serum concentration at time t after injection n requires computing a sum of exponentially decaying contributions from all prior doses: C(t) = Σ [Di × e−kel × (t − ti)] for all previous doses i. In Excel, this requires correctly referencing each injection timestamp, applying the right kel per compound, and summing across the full dose history. A single cell reference error — copying a formula one row too many, referencing the wrong half-life cell — produces a concentration value that looks plausible but is numerically wrong. The error is invisible unless you audit the formulas by hand.
A spreadsheet models the protocol you planned, not the protocol you executed. If you inject a day late, miss a dose, or change your dose mid-protocol, your Excel model is stale from that moment forward. Manually rebuilding the concentration timeline from a revised injection history — accounting for the shifted accumulation state — requires reconstructing the entire formula chain. In practice, people do not do this. They run with a model that diverges increasingly from reality.
A spreadsheet is a static grid. It has no mechanism to watch your concentration curve in real time and notify you when a projected trough is approaching. You would need to check the model manually, on every dosing day, for every compound, and interpret the output yourself. For a three-compound stack with different dosing frequencies, this becomes a daily audit task.
Adding a compound to your protocol means building a new exponential decay model from scratch — new kel, new Racc, new concentration timeline, new overlay chart. There is no library to pull from. Every compound is a manual engineering exercise. The probability of introducing a formula error increases with each compound added.
The table below evaluates both approaches across the attributes that determine whether your steady-state calculations remain accurate and actionable throughout a real protocol.
| Attribute | Halflife — Peptide & GLP-1 Log | Excel / Manual Spreadsheet |
|---|---|---|
| Error Risk | Zero formula error risk kel, Racc, Css, and PTR computed automatically from citation-backed half-life values. No manual cell references, no copy-paste errors. |
High and silent A single incorrect cell reference in an exponential decay formula produces a plausible-looking but numerically wrong concentration value. No built-in error detection. |
| Time Investment | Seconds per compound Select compound from library, confirm dose and frequency. Accumulation model is built and displayed immediately. No formula construction required. |
Hours per compound Build decay formula from scratch, source half-life value, construct accumulation sum, chart the output. Rebuild for every new compound or dose change. |
| Dynamic Adjustments | Real-time, log-driven Every logged injection — including late, early, or missed doses — immediately recalculates the concentration curve and updates projected trough timing. |
Manual rebuild required Any deviation from planned protocol — dose change, missed injection, shifted schedule — requires manual revision of the entire formula chain. |
| Visual Plotting | Live native curve Real-time concentration-time curve driven by your actual injection log. Multi-compound overlay available. Updates on every logged dose. |
Manual chart construction Chart is built once from the planned protocol. Does not update automatically. Multi-compound overlay requires merging separate data tables. |
| Trough Alerts | Predictive push notifications Fires before projected trough crosses your configured threshold — not after. Works per-compound on your actual injection cadence. |
None Spreadsheets have no notification layer. Trough timing must be manually checked on every dosing day. |
| Compound Library | 45+ citation-backed profiles Half-life values sourced from published PK studies. Automatically loaded when you select a compound — no manual sourcing required. |
User-sourced, unvalidated You must find, evaluate, and manually enter half-life values for each compound. Sourcing errors propagate into every downstream calculation. |
Halflife is not a calculator that does one step of the framework above and hands the output back to you. It runs all five steps continuously, across every compound in your active stack, driven by your real injection log rather than a hypothetical plan.
The steady-state framework is not academic. Each output from the five steps has a direct practical implication for how you structure your protocol:
Before your protocol begins — or at any point while it is running — five pharmacokinetic parameters fully define what your blood concentration curve looks like:
A spreadsheet can compute these once, for one compound, for the protocol you planned. Halflife computes all five continuously, for your full stack, from the protocol you are actually executing — and alerts you when the trough is coming before you miss it.
Halflife automates every formula in this guide — accumulation multipliers, decay curves, trough alerts — across your full peptide and GLP-1 stack in real time.
Download Halflife — Peptide & GLP-1 Log →